Sleep Disorders and Tumor Immune Microenvironment

Launched by SHANGHAI ZHONGSHAN HOSPITAL · Apr 16, 2025

Keywords

ClinConnect Summary

This clinical trial, titled "Impact of Sleep Disorders on Tumor Immune Microenvironment and Clinical Outcomes in Lung Cancer," aims to explore how sleep disorders, like insomnia and obstructive sleep apnea, affect lung cancer patients. Specifically, it will look at how these sleep issues might change the immune environment around tumors and influence how well patients respond to treatments like immunotherapy. The study will follow around 400 newly diagnosed lung cancer patients over three years to gather important information about their health and treatment outcomes.

To join the study, participants must be adults aged 65 to 75 who have recently been diagnosed with stage III or IV non-small-cell lung cancer and are not currently receiving any treatments. They will undergo tests to confirm their sleep disorder status, and those who qualify will be monitored throughout the trial. This research is crucial as it may help doctors understand how sleep affects cancer treatment and could lead to better care for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with newly diagnosed stage III-IV non-small-cell lung cancer (NSCLC) not receiving systemic therapy (chemotherapy, immunotherapy, or radiotherapy)
• Exclusion Criteria:
• • Patients with severe mental illness, other malignant tumors, or receiving sleep medication